We are live on ! Find out more
PR

PSP Research Portfolio holdings

AUM $188M
This Fund
S&P 500
This Quarter Est. Return
+2.42%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$141M
AUM Growth
+$26.9M
Cap. Flow
+$26.9M
Cap. Flow %
19.02%
Top 10 Hldgs %
81.88%
Holding
105
New
20
Increased
10
Reduced
43
Closed
26

Top Buys

Rank Stock Value
1
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$35.6M
2
SERA icon
Sera Prognostics
SERA
+$6.17M
3
IRON icon
Disc Medicine
IRON
+$555K
4
GLUE icon
Monte Rosa Therapeutics
GLUE
+$535K
5
ARDX icon
Ardelyx
ARDX
+$529K

Top Sells

Rank Stock Value
1
TVTX icon
Travere Therapeutics
TVTX
+$584K
2
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$554K
3
CGON icon
CG Oncology
CGON
+$552K
4
BLTE
Belite Bio
BLTE
+$551K
5
APLS
Apellis Pharmaceuticals
APLS
+$549K

Sector Composition

Rank Sector Weight
1 Healthcare 24.4%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
STOK icon
51
Stoke Therapeutics
STOK
$2.14B
$391K 0.28%
12,000
-4,621
-28% -$152K
KOD icon
52
Kodiak Sciences
KOD
$2.47B
$381K 0.27%
10,000
-9,418
-49% -$243K
DYN icon
53
Dyne Therapeutics
DYN
$4.9B
$363K 0.26%
20,000
-1,535
-7% -$26.5K
TRVI icon
54
Trevi Therapeutics
TRVI
$2.56B
$358K 0.25%
+30,000
New +$336K
NTLA icon
55
Intellia Therapeutics
NTLA
$1.84B
$345K 0.24%
+26,900
New +$343K
PTGX icon
56
Protagonist Therapeutics
PTGX
$9.74B
$316K 0.22%
3,000
-3,121
-51% -$276K
MDGL icon
57
Madrigal Pharmaceuticals
MDGL
$12.4B
$314K 0.22%
600
-292
-33% -$140K
SUPN icon
58
Supernus Pharmaceuticals
SUPN
$2.61B
$310K 0.22%
6,000
-4,758
-44% -$242K
TNGX icon
59
Tango Therapeutics
TNGX
$4.33B
$301K 0.21%
+14,400
New +$200K
ERAS icon
60
Erasca
ERAS
$6.55B
$280K 0.2%
+17,327
New +$205K
ELVN icon
61
Enliven Therapeutics
ELVN
$4.5B
$274K 0.19%
+7,000
New +$194K
SYRE icon
62
Spyre Therapeutics
SYRE
$8.21B
$260K 0.18%
5,159
-10,681
-67% -$403K
ZYME icon
63
Zymeworks
ZYME
$2.08B
$250K 0.18%
10,000
-10,312
-51% -$244K
XENE icon
64
Xenon Pharmaceuticals
XENE
$6.22B
$244K 0.17%
4,200
-7,478
-64% -$345K
ORKA
65
Oruka Therapeutics
ORKA
$6.62B
$244K 0.17%
+4,968
New +$173K
CELC icon
66
Celcuity
CELC
$4.67B
$228K 0.16%
2,000
-3,244
-62% -$354K
KALV
67
DELISTED
KalVista Pharmaceuticals
KALV
$217K 0.15%
+10,795
New +$174K
LEGN icon
68
Legend Biotech
LEGN
$4.03B
$217K 0.15%
12,000
-12,397
-51% -$236K
ALKS icon
69
Alkermes
ALKS
$8.24B
$212K 0.15%
6,000
-13,280
-69% -$412K
APGE icon
70
Apogee Therapeutics
APGE
$10.2B
$210K 0.15%
2,500
-4,484
-64% -$326K
UTHR icon
71
United Therapeutics
UTHR
$22.2B
$208K 0.15%
350
-730
-68% -$364K
EWTX icon
72
Edgewise Therapeutics
EWTX
$4.82B
$205K 0.14%
+6,500
New +$187K
SMMT icon
73
Summit Therapeutics
SMMT
$11.4B
$194K 0.14%
+10,223
New +$165K
ORIC icon
74
Oric Pharmaceuticals
ORIC
$1.43B
$165K 0.12%
+13,000
New +$148K
CMPX icon
75
Compass Therapeutics
CMPX
$436M
$159K 0.11%
+30,000
New +$173K
1 2
3
4 5

Similar funds

IJWM
Inman Jager Wealth Management Hattiesburg, Mississippi $188M AUM 19.49% 1-Year Est. Return
TCPG
Trivant Custom Portfolio Group San Diego, California $188M AUM 23.55% 1-Year Est. Return
KCPT
Kingstone Capital Partners Texas Frisco, Texas $188M AUM 26.67% 1-Year Est. Return
DWS
Dynamic Wealth Strategies Granite Bay, California $188M AUM 18.55% 1-Year Est. Return
RMSCM
R.M. Sincerbeaux Capital Management New York $188M AUM 12.59% 1-Year Est. Return
AWP
Astra Wealth Partners Jersey City, New Jersey $188M AUM 26.79% 1-Year Est. Return
AIMA
Ables Iannone Moore & Associates Savannah, Georgia $188M AUM 26.75% 1-Year Est. Return
CFP
Comprehensive Financial Planning East Petersburg, Pennsylvania $188M AUM 48.26% 1-Year Est. Return

PSP Research's Q1 2026 Portfolio in Review

As of Q1 2026, PSP Research held 105 positions worth $141M, up 24% from $114M the previous quarter. Its ten largest holdings account for 82% of the portfolio.

PSP Research deployed $26.9M of net new capital in Q1 2026, opening 20 new positions and adding to 10 existing holdings. Its largest new stake was State Street SPDR S&P Biotech ETF: 284,900 shares worth $36.4M.

By sector, the portfolio is most concentrated in Healthcare at 24% of assets, down from 39% a quarter earlier.

On the sell side, the largest reduction was Amylyx Pharmaceuticals, an estimated $470K trimmed.

  • PSP Research's largest Q1 2026 buy was State Street SPDR S&P Biotech ETF: 284,900 shares worth $36.4M.
  • PSP Research added most to Alnylam Pharmaceuticals in Q1 2026, an estimated $50K increase.
  • PSP Research's biggest Q1 2026 reduction was Amylyx Pharmaceuticals, cutting an estimated $470K.
  • PSP Research fully exited Travere Therapeutics in Q1 2026, selling an estimated $584K.
  • PSP Research's ten largest holdings make up 82% of its $141M portfolio in Q1 2026.
  • PSP Research opened 20 new positions and closed 26 in Q1 2026.
  • PSP Research's portfolio value rose 24% quarter-over-quarter to $141M.

Based on PSP Research's 13F filing for Q1 2026, filed 17 Apr 2026.